Evidence map›Paper›PMID 39310124›Full record

ArticleAmerican journal of clinical and experimental immunology2024

Ultrashort plasma cell-free DNA: a novel non-invasive marker for cancer diagnostics.

Guodong Zhao

Abstract read
In one paragraph

Article in American journal of clinical and experimental immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Guodong ZhaoDepartment of Spleen and Stomach Diseases, Kunshan Hospital of Traditional Chinese Medicine Kunshan 215300, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have shown that ultrashort plasma cell-free DNA (uscfDNA), a novel type of cfDNA fragment approximately 50 nucleotides long, differs from conventional monocyte-derived cfDNA in several aspects, including specific extraction requirements and a higher incidence of tumor-specific genetic alterations. uscfDNA shows promise in enhancing liquid biopsy sensitivity for cancer detection, with distinct methylation profiles observed in cancer patients. These findings suggest uscfDNA analysis could significantly improve non-invasive cancer diagnostics, offering new avenues for early detection and personalized medicine strategies.

Indexed as

mncfDNAplasmauscfDNA

Identifiers

PMID39310124
PMCPMC11411157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.